Company intelligence / Profile preview

EicOsis Human Health

Davis, California, United States

Ownership: Private
Development stage: Other

Overview

EC5026, a small molecule sEH inhibitor, has completed Phase 1a trials showing safety, favorable pharmacokinetics for once-daily oral dosing, and no adverse effects; Phase 1b ongoing, with planned patient studies in neuropathic pain due to spinal cord injury.

Therapeutic areas: CardiovascularImmunologyNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

EC5026

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on EicOsis Human Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EicOsis Human Health.

Explore the full profile